Bypassing therapy is essential for the haemostatic management of patients with haemophilia A with inhibitor (PWHA-inh), but the therapeutic effects are inconsistent. We previously reported that activated prothrombin complex concentrates (aPCC) activated factor (F)VIII in vitro, and was mediated mainly by the activated FVII (FVIIa) contained in aPCC. We have extended those studies to assess global coagulation in whole blood from 18 PWHA-inh in the co-presence of aPCC and FVIII using Ca 2+ -triggered rotational thromboelastometry. The clot times (CTs) in the presence of both aPCC (0Á05 iu/ml) and recombinant (r)FVIII (1 iu/ml) ex vivo were shortened compared to the aPCC alone (P < 0Á01). These enhancing effects of rFVIII were observed, irrespective of recognizing inhibitor epitopes; however, the clot formation time and 'a'-angle were not significantly different. In samples from 7 PWHA-inh post-infusion of aPCC (70-80 iu/kg), only the CTs were shortened in the presence of rFVIII ex vivo compared to its absence (P < 0Á05), indicating that the enhanced activity centred on the initiation phase of coagulation. Furthermore, experiments in the co-presence of rFVIIa and rFVIII demonstrated that FVIII accelerated only the CTs. We concluded that FVIII/FVIIa-related coagulation mechanism enhanced global haemostatic function by the co-presence of bypassing agents and FVIII in PWHA-inh.
Factor (F)VIII, a plasma protein that is deficient in individuals with the severe congenital bleeding disorder, haemophilia A (HA), functions as a cofactor in the tenase complex, which is responsible for phospholipid (PL)-dependent activated FIX (FIXa)-mediated activation of FX (Mann et al, 1990) . The FVIII molecule is arranged into three domains (A1-A2-B-A3-C1-C2 in order) and processed into a series of heterodimers, generating a heavy chain (HCh) consisting of A1 and A2 domains together with heterogeneous proteolysed B domain linked to a light chain (LCh) consisting of A3, C1, and C2 domains (Hoyer, 1981) . The catalytic efficiency of FVIII in the tenase complex is significantly enhanced approximately 10 6 -fold by conversion to activated FVIII (FVIIIa) through limited proteolysis at Arg 372 , Arg 740 and Arg 1689 by thrombin (Eaton et al, 1986) , reflecting the propagation and amplification phases of the coagulation processes.
Our earlier studies on FVIIIa-related coagulation mechanisms demonstrated that FVIIa and tissue factor (TF, also termed FIII) complexes activated FVIII in vitro by limited proteolysis at Arg 372 and Arg 740 in the HCh more rapidly than that mediated by thrombin (Soeda et al, 2010) . This reaction appeared to promote a 'priming' mechanism that would probably lead to the generation of small amounts of FVIIIa physiologically in the initiation phases of coagulation. In addition, this activation was evident even in the presence of von Willebrand factor (VWF) and anti-FVIII inhibitor alloantibodies (alloAbs) (Soeda et al, 2010; Yada et al, 2011) . Recent investigations using an animal model have focused on the potential physiological role of FVIII activation by TF/ FVII/FXa complexes in thrombogenesis (Kamikubo et al, 2017) , but the significance of this mechanism related to haemophilia therapy remains to be clarified.
FVIII inhibitors develop as alloAbs in approximately 20% of PWHA after multiple infusions of FVIII concentrates (Oldenburg et al, 2000) . The reduction or disappearance of FVIII activity (FVIII:C) caused by anti-FVIII inhibitors is associated with impairment of FVIII and/or FVIIIa function, mediated by binding to functionally essential regions on FVIII. Inhibitory epitopes have been localized to one or more of the A2, A3-C1, and C2 domains (Prescott et al, 1997; Zhong et al, 1998) . Haemostatic treatment of PWHA with inhibitor that are classified as high responders particularly depends on 'bypassing therapy'. Recombinant FVIIa (rFVIIa; NovoSeven â , Novo Nordisk, Bagsvaerd, Denmark) and plasma-derived activated prothrombin complex concentrates (aPCC; FEIBA â , Shire Lexington, MA, USA) are currently available for this purpose. In this context, Klintman et al (2010) reported that mixtures of FVIII and bypassing agents added to plasma samples from PWHA with inhibitor in vitro, compared to bypassing agents alone, synergistically potentiated thrombin generation. In addition, our earlier studies on haemostatic potential in the co-presence of FVIII and aPCC demonstrated that preactivation of FVIII in the presence of TF and FVII/FVIIa, contained in the aPCC, contributed to enhanced coagulation activity irrespective of the presence of anti-FVIII inhibitors (Yada et al, 2013) . It appeared, therefore, that concomitant therapy with FVIII and aPCC might provide better haemostatic management for PWHA with inhibitor. Those findings were based, however, on assays using purified reactants in vitro, and the combined effects of FVIII and aPCC in physiological whole blood remained to be determined. We have now extended our earlier investigations to examine the impact of mixtures of FVIII and aPCC on global coagulation mechanisms in whole blood samples from PWHA with inhibitor using rotational thromboelastometry (ROTEM).
Materials and methods
This study was approved by the Medical Research Ethics Committee of Nara Medical University, Japan (No. 1038).
Reagents
Recombinant (r)FVIII (Advate â ) and aPCC (FEIBA â ) preparations were generously provided by Baxalta Japan Limited (Tokyo, Japan). rFVIIa (NovoSeven â ) was purchased from Novo Nordisk (Bagsvaerd, Denmark).
Anti-FVIII inhibitor alloAbs
Sixteen anti-FVIII inhibitor alloAbs were obtained from whole blood (3 ml) taken from Japanese PWHA with high titre inhibitors. Immunoglobulin G (IgG) fractions were prepared using protein A-Sepharose (Amersham Biosciences, Uppsala, Sweden). The anti-FVIII inhibitor activities of antibody IgGs were determined using the Bethesda assays (Kasper et al, 1975) . Recognized epitope profiles of the inhibitor antibodies were determined by sodium dodecyl sulfate polyacrylamide gel electophoresis and Western blotting using isolated FVIII fragments (Matsumoto et al, 2012) . Nine of the inhibitors recognized epitopes in the FVIII HCh (mainly the A2 domain) and seven antibodies reacted with epitopes in the LCh (mainly the C2 domain).
Blood samples
Whole blood was obtained by venepuncture from PWHA with inhibitor (n = 18) or without inhibitor (n = 2) and from healthy volunteers (n = 20) after obtaining informed consents following the local ethical guidelines. Whole blood was taken into tubes containing 1:9 volume of 3Á2% (w/v) trisodium citrate and left at room temperature for 30 min prior to assessment by ROTEM. Blood samples containing bypassing agents were obtained 15 min post-infusion of aPCC (n = 7) or rFVIIa (n = 3). Samples were prepared for three experimental procedures as follows.
Experiment A. Whole blood obtained from PWHA with inhibitor was mixed with aPCC (final concentration; f.c., 0Á05 iu/ml) or rFVIIa (f.c. 25 nmol/l) for 15 min, followed by the addition of rFVIII (f.c. 1Á0 iu/ml).
Experiment B. Whole blood obtained from PWHA without inhibitor was pre-incubated with anti-FVIII inhibitor IgG (f.c. 20 BU/ml) for 1 h. The reactant whole blood was similarly mixed with aPCC (f.c. 0Á05 iu/ml) for 15 min, followed by the addition of rFVIII (f.c. 1Á0 iu/ml).
Experiment C. rFVIII (f.c. 1Á0 iu/ml) was added to whole blood obtained from PWHA with inhibitor 15 min after administration of aPCC (70-80 iu/kg) or rFVIIa (90-100 lg/ kg). The final concentration of aPCC or rFVIIa in whole blood was calculated using the following formula; therapeutic dose (iu/kg or lg/kg)/80 = final concentration (iu/ml or lg/ml, respectively). Hence, administration of aPCC (80 iu/kg) or rFVIIa (90 lg/kg) corresponded to~1 iu/ml or~1Á2 lg/ml (25 nmol/l), respectively (Haku et al, 2014) .
ROTEM
ROTEM was performed 30 min after venepuncture using the Whole Blood Haemostasis Analyser â (Pentapharm, Munich, Germany). Blood (300 ll) was mixed with 20 ll CaCl 2 (100 mmol/l) after pre-incubation at 37°C, placed in the plastic cup and the viscosity of clot formation was monitored at 37°C (Nogami, 2016) . The coagulation process was assessed using the clot time (CT; the time until detection of clot firmness at 2 mm amplitude) and the clot formation time (CFT; the time until detection of clot firmness of 20 mm amplitude). Angle (a) is derived from a tangent line (Nogami, 2016) .
Data analyses
All experiments were performed in triplicate, and the mean values were determined. Significant differences were determined by the Wilcoxon t-test and the Mann-Whitney U-test. P-values < 0. 05 were considered as statistically significant.
Results
Impact of aPCC and rFVIII added to whole blood ex vivo from PWHA with inhibitor
We first examined the effects of adding aPCC and rFVIII together to whole blood from PWHA with inhibitor. We had previously demonstrated thromboelastograms of whole blood from PWHA with inhibitor in the presence of 0Á6-1Á1 iu/ml aPCC (corresponding to clinical therapeutic concentrations) added ex vivo were enhanced more than in whole blood from patients that had received aPCC treatment (50-100 iu/kg; almost equal to 0Á6-1Á1 iu/ml) (Furukawa et al, 2015) . Moreover, we had demonstrated that very low concentrations of aPCC (0Á05 iu/ml), equivalent to approximately one-tenth of therapeutic concentrations, activated FVIII directly in vitro (Yada et al, 2013 ). In the current ex vivo experiments, therefore, thromboelastograms were determined using aPCC at a f.c. of 0Á05 iu/ml (Experiment A). Activated prothrombin complex concentrate was added ex vivo to whole blood from PWHA with inhibitor [n = 18, mean AE standard deviation (SD); 82 AE 125 BU/ml] prior to the addition of rFVIII (f.c. 1Á0 iu/ml) and assessment of CaCl 2 -triggered ROTEM [native coagulation (NATEM) mode] as described in Methods. Figure 1A illustrates a representative thromboelastogram in the presence of rFVIII alone, aPCC alone and both aPCC and rFVIII ex vivo. As expected, the addition of FVIII resulted in little improvement in the thromboelastogram. The addition of aPCC significantly improved coagulation potential, however, and subsequent addition of rFVIII further enhanced this activity. The ROTEM parameters, CT mainly reflecting the initiation phase of coagulation process, together with CFT and a, mainly reflecting the amplification and propagation phases of coagulation, were analysed (Fig 1B) . In each case, all parameters markedly improved to within the normal range after the addition of aPCC ex vivo. Moreover, the CTs obtained in the presence of both aPCC and rFVIII were further significantly shortened compared to aPCC alone (1,140 AE 485 s and 1,326 AE 404 s, P < 0Á005). In contrast, there were no significant differences in CFT and 'a' between the samples in the co-presence of aPCC and rFVIII and those with aPCC alone.
Impact of aPCC and rFVIII in whole blood from PWHA without inhibitor supplemented with anti-FVIII inhibitor IgG
To examine the potential influence of pre-existing components in these mechanisms, including other clotting factors, FVIII inhibitor titre and specific properties of individual antibodies, purified IgG was prepared from inhibitor plasmas (n = 16) and incubated with whole blood from a PWHA without inhibitor. Nine of these inhibitor IgG's recognized epitopes against the HCh (mainly A2 epitope) and 7 cases recognized epitopes against the LCh (mainly C2 epitope). Whole blood from the non-inhibitor PWHA was mixed with anti-FVIII IgG and adjusted to 20 BU/ml (f.c.), prior to incubation with aPCC (0Á05 iu/ml), the subsequent addition of rFVIII (1Á0 iu/ml) and evaluation by ROTEM (Experiment B).
Figure 2 panels (a) illustrate representative thromboelastograms after the addition of either rFVIII alone, aPCC alone, or both aPCC and rFVIII in whole blood mixed with anti-HCh (A2 epitope; panel A) or anti-LCh (C2 epitope; panel B) inhibitors. In all instances, the addition of rFVIII alone had little effect on the thromboelastograms. The addition of aPCC markedly improved coagulation potential, however, and the co-presence of both rFVIII and aPCC further enhanced this activity. In addition, ROTEM parameters after the addition of aPCC alone were improved to within the normal range irrespective the type of inhibitor epitope (Fig 2A and B, panel b) . Specifically, the CTs obtained in the co-presence of aPCC and rFVIII were markedly shortened compared to those in the presence of aPCC alone (anti-HCh; 504 AE 87 s and 1,034 AE 317 s, P < 0Á005, anti-LCh; 682 AE 129 s and 1,282 AE 232 s, P < 0Á01), and the CFTs also demonstrated significant differences between treatment with aPCC/rFVIII and aPCC alone (anti-HCh; 150 AE 63 s and 208 AE 44 s, P < 0Á01, anti-LCh; 192 AE 43 s and 243 AE 40 s, P < 0Á05). No significant differences in 'a' were observed, however (data not shown).
Effects of rFVIII on post-aPCC-infusion whole blood from PWHA with inhibitor
The effects of adding rFVIII (1Á0 iu/ml) ex vivo to whole blood from PWHA with inhibitor (n = 7, 247 AE 181 BU/ml) after treatment with aPCC (70-80 iu/kg) were also examined by ROTEM. rFVIII was added to the whole blood samples obtained 15 min post-aPCC administration (Experiment C). A representative thromboelastogram is shown in Fig 3A. In all cases, the coagulation potential had improved after treatment with aPCC, and the addition of rFVIII ex vivo to the whole blood samples demonstrated further enhancement. In each instance the CT in the presence of rFVIII was significantly shorter relative to that obtained in its absence (1,187 AE 462 s and 1,689 AE 643 s, P < 0Á05) (Fig 3B) . The CFT and 'a' were not significantly affected by the addition of rFVIII, however.
The co-presence of rFVIIa and rFVIII in whole blood from PWHA with inhibitor
The presence of FVIII with aPCC appeared to significantly influence the CT in ROTEM, reflecting the initiation phase of coagulation, and the present results supported our earlier data on the role of FVIIa in aPCC-induced FVIII activation (Yada et al, 2013) . To further examine these mechanisms, therefore, similar experiments were repeated with rFVIIa and rFVIII added to whole blood from PWHA with inhibitor. We had previously determined that the improvement effect at 25 nmol/l rFVIIa corresponded to that at the clinical therapeutic dose (90 lg/kg) using ROTEM in whole blood from PWHA with inhibitor (Furukawa et al, 2015) . The present ex vivo experiments were performed, therefore, using rFVIIa at a concentration of 25 nmol/l. rFVIIa was mixed with whole blood from PWHA with inhibitor (n = 7; 198 AE 78 BU/ml) ex vivo, and then incubated with rFVIII (f.c. 1Á0 iu/ml) prior to the Ca 2+ -triggered ROTEM. Fig 4A illustrates a representative thromboelastogram in the presence of rFVIII alone, rFVIIa alone, and both of rFVIIa and rFVIII. As before, the addition of FVIII resulted in little improvement of the thromboelastogram. A significant coagulant effect was observed with rFVIIa, further enhancement was evident in the co-presence of rFVIIa with rFVIII. In each case, all ROTEM parameters were markedly improved to within the normal range after the ex vivo addition of rFVIIa (Fig 4B) . The CT in the combined presence of FVIIa and rFVIII was significantly shorter that in the presence of rFVIIa alone (776 AE 220 s and 872 AE 226 s, P < 0Á05). No significant differences in CFT and 'a' were seen between the co-presence of rFVIIa with rFVIII and rFVIIa alone (Fig 4B) . Similar to the experiments described above, the effects of adding rFVIII (1Á0 iu/ml) ex vivo to whole blood from PWHA with inhibitor (n = 3, 80 AE 104 BU/ml) after treatment with rFVIIa (90 lg/kg), were further examined by ROTEM. rFVIII was added to the whole blood samples obtained 15 min post-rFVIIa administration. Figure 5A illustrates a representative thromboelastogram. The coagulant effect of rFVIIa was clearly evident in the post-infusion samples, and the addition of rFVIII to the whole blood ex vivo demonstrated a further significant improvement in coagulation potential. The number of patients was relatively small, but, as before, in each instance the CT in the presence of rFVIII was significantly shorter relative to that obtained in its The addition of aPCC and rFVIII ex vivo to whole blood from patients with Haemophilia A without inhibitor incubated with anti-FVIII IgG -Whole blood from patients with Haemophilia A without inhibitor was preincubated with anti-FVIII inhibitor IgG (f.c. 20 BU/ml, (A) anti-HCh n = 9,(B) anti-LCh n = 7). aPCC (f.c. 0Á05 iu/ml) was then added prior to the further addition of rFVIII (f.c. 1Á0 iu/ml) and evaluation by ROTEM. Panel (a); A representative thromboelastogram in the presence of FVIII alone, aPCC alone, and both aPCC and rFVIII. Panel (b); Boxplots of parameter changes of parameters in the presence of rFVIII, aPCC, and aPCC and rFVIII. The median values are depicted within the boxes. The boxes end at the 25th and 75th percentiles, and the whiskers extend to the furthest points that are not outliers. Outliers are depicted as open dots. Significant differences are defined as P < 0Á05. The upper and lower dotted lines show the 95% confidence interval of parameters from normal controls. aPCC, activated prothrombin complex concentrate; CFT, clot-formation time; CT, Clot time; f.c., final concentration; FVIII, factor VIIII; N.S., not significant; rFVIII, recombinant factor VIII; TEM, thromboelastometry. [Colour figure can be viewed at wileyonlinelibrary.com] absence, whilst the CFT and 'a' were not gnificantly affected by the addition of rFVIII (Fig 5B) .
Discussion
The present investigation demonstrated for the first time that the co-presence of aPCC with FVIII significantly enhanced coagulation potential relative to aPCC alone in whole blood from PWHA. Moreover, the enhancing effects were observed even in the presence of anti-FVIII inhibitor antibody. Our earlier studies using a purified assay system demonstrated that aPCC itself activated FVIII directly through limited proteolysis at Arg 740 and Arg 372 , and that FVIIa contained in the aPCC complex played a central role in the early phases of coagulation by initiating rapid aPCC-mediated FVIII activation in the presence of TF (Yada et al, 2013) . FXa and thrombin appeared to participate in these reactions sequentially at later time points. The current data are in keeping with the earlier conclusions and confirmed that coagulation potential in whole blood under near-physiological conditions was most effectively promoted by the co-presence of FVIII with aPCC or rFVIIa, although the ROTEM technique utilizes a shear rate of 50/s which is lower than that of the venous flow at 240/s. The modern cell-based coagulation model specifies that FVIIa/TF initiates blood coagulation and promotes FXa generation, leading to thrombin generation and propagating fibrin formation (Hoffman & Monroe, 2001) . Our earlier studies highlighted the possibility that FVIIa/TF physiologically activates FVIII as well as FX in this initial coagulation phase (Soeda et al, 2010) . More recently, we have further examined FVIII(a)-FVIIa/TF interactions and identified both an extrinsic and two potential intrinsic mechanisms of FXa generation mediated by FVIIa/TF-activated FVIIIa (FVIIIaVIIa/TF) and FVIII/TF in the early coagulation process (Furukawa et al, 2016) . In those studies, intrinsic FXa generation with FVIIIa VIIa/TF was detected even in the presence of either VWF or tissue factor pathway inhibitor (TFPI) (Furukawa et al, 2016) . In addition, a novel study using a mouse model with a relatively mild thrombogenic phenotype demonstrated that the FVIIa/TF/FXa ternary complex activated FVIII selectively, resulting in enhanced thrombin formation in primary coagulation reactions (Kamikubo et al, 2017) . The new findings would provide convincing evidence that the co-presence of FVIII with aPCC or rFVIIa leads to FVIII activation before coagulation amplification by thrombin-dependent mechanisms.
Specific ROTEM parameters, assessed using three different experimental protocols, in the presence of aPCC and FVIII consistently demonstrated shortened CTs but little change in CFT and 'a'. The CT mainly reflects the initiation phase of coagulation process (Nogami, 2016) , our results were in accordance, therefore, with the likelihood that FVIIa contained in aPCC interacted with FVIII in this mechanism (Yada et al, 2013) . However, Klintman et al (2010) reported that, using a platelet-poor plasma-based thrombin generation assay in vitro, the combination of aPCC and FVIII had synergistic effects, whilst rFVIIa and FVIII showed additive effects. We were not able to determine whether the enhancing effects of bypassing agent and FVIII were synergistic or additive. This may have been due to the limited sensitivity of ROTEM using whole blood. Nevertheless, the 'a' parameter mainly reflects the amplification and/or propagation phase of coagulation (Nogami, 2016) and was little affected in the current experiments. The data provided strong evidence, therefore, that the co-presence of aPCC with FVIII could positively augment the initiation phase of coagulation in whole blood at low shear stress.
Our present results using patients' whole blood could provide challenging possibilities for the use of bypassing therapy with a combination of FVIII and aPCC in not only congenital but also acquired PWHA with inhibitors. It could be expected that treatment in these circumstances would be restricted by the rapid clearance of FVIII from the circulating blood by the formation of inhibitor antibody-FVIII complexes, but, unexpectedly in our studies, the beneficial effects of potential combination therapy appeared to be independent of the presence of high-titre FVIII inhibitors. The findings could have been influenced by the following mechanisms; (i) aPCC (FVIIa)-mediated FVIII reactions may be extremely rapid, or (ii) the binding of FVIII to anti-FVIII antibody and/or on the inhibition of FVIII function might be relatively slow. Nevertheless, precise reasons remain to be established. In addition, the positive reactions in whole blood appeared to be irrespective of the epitopes recognized by the specific inhibitors, and FVIII activity was elevated in the presence of aPCC (and rFVIIa) in mixtures incubated with either anti-A2 or anti-C2 epitopes. It is well known, however, that ROTEM does not reflect the inactivation of FVIIIa, and detailed analysis of our results indicated that anti-C2 type 1 preparations moderated this phase of aPCC-or rFVIIamediated reactions in association with delayed cleavage at Arg 336 (Yada et al, 2011 (Yada et al, , 2013 , in keeping with the suggestion that inhibitor kinetics could be dependent on the type anti-C2 antibody (Gawryl & Hoyer, 1982) . The present results add to our earlier investigations and could offer a novel approach to therapy in PWHA, paticularly in some difficult clinical circumstances, for example, where conventional aPCC (and rFVIIa) infusions fail to control haemorrhagic symptoms, or for PWHA with inhibitor who require management of symptomatic bleeding during immune tolerance induction therapy. Nonetheless, the present data were based on ex vivo experiments, and further research is needed, including clinical trials associated with concomitant therapy using aPCC (or rFVIIa) and rFVIII, to validate the efficacy of this strategy.
